Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SynBioSe-2
NL-OMON52462Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in systemic lupus erythematosus (SLE) comparing Belimumab + rituximab + standard therapy with Standard of care (2 arms). Primary endpoint: Treatment failure rate. Started Oct 2018; status: recruiting.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON52462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52462.